Publication | Closed Access

Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells

Withaferin ATumor BiologyPancreatic CancerOncogenic AgentMedicineCancer BiologyTumor SuppressorRadiation OncologyOncologyCell BiologyCancer ResearchPi3k/akt PathwaySynergistic Antitumor Activity